# Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT05673967** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma (RRMM)

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT05673967
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2024-09-12
- **Final completion:** 2025-03-28
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673967, "Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05673967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*